Related Experiment Video

Updated: Mar 5, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

703

Redefining the role of biomarkers in heart failure trials: expert consensus document

Frank Kramer1, Hani N Sabbah2, James J Januzzi3

  • 1BAYER AG, Experimental Medicine Cardiovascular/Hematology, Aprather Weg 18a, 42133, Wuppertal, Germany. frank.kramer@bayer.com.

Heart Failure Reviews
|March 24, 2017
PubMed

Insights

Novel treatments for heart failure are in development. This review examines molecular, imaging, and digital biomarkers, discussing their capabilities and limitations in heart failure drug development and clinical management.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Drug Development

Background:

  • Heart failure (HF) is a significant and growing cardiovascular disease with major health and societal impacts.
  • There is a high unmet need for effective novel treatments for heart failure.
  • Biomarkers are crucial for patient stratification and monitoring in clinical trials and patient management.

Purpose of the Study:

  • To provide an overview of the role of biomarkers in heart failure drug development.
  • To discuss the capabilities and limitations of various biomarker types in this context.

Main Methods:

  • Review of available molecular biomarkers.
  • Review of available imaging biomarkers.
  • Review of available device-derived digital biomarkers.

Main Results:

  • Biomarkers are essential tools in the development of new heart failure therapies.
  • Different biomarker types offer unique advantages and face specific challenges.
  • Understanding biomarker utility is key to successful drug development and clinical application.

Conclusions:

  • Biomarkers are integral to advancing heart failure drug development.
  • A comprehensive understanding of biomarker capabilities and limitations is necessary.
  • Continued research into novel biomarkers will aid in addressing the unmet needs in heart failure treatment.

Keywords:
BiomarkerClinical trialDrug developmentHeart failureImagingMedical device

More Related Videos

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

884

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
668
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
496
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K